No Prescription |
 |
 | ||
|
COLOSPA Colofac |
|
| ||
No Prescription » Prescription Drugs 4 » COLOSPA Colofac Category : Antispasmodic; smooth muscle relaxant. Mebeverine has a Online non-specific relaxant effect on vascular cardiac and other smooth muscle. Studies indicate that the spasmolytic activity of mebeverine is not restricted to one particular system but the compound possesses a polyvalent spasmolytic action in which at least three types of mechanisms are involved:- a Online musculotropic action involving calcium ion exchange and stabilization of excitable membranes- a competitive antimuscarinic activity of about 0.05 - 0.1 times that of atropine- a local anaesthetic activity together with potentiation of sympathetic inhibitory influences due to blockade of noradrenaline uptake into sympathetic nerve endings Buy COLOSPA Colofac and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About COLOSPA Colofac: Product Type: Prescription Drugs 4 COLOSPA ( Colofac Generic Mebeverine ) COLOSPA (Colofac Generic Mebeverine) Colofac Generic Mebeverine 135mg 135mg Tabs 4 x 100 Tablets 100 Tablets 2 x 100 Tablets 30 (3 x 10) Colofac Generic Mebeverine COLOSPA
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
